Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels, posing a significant global health burden. They encompass a wide range of conditions, including coronary artery disease, heart failure, stroke, and peripheral artery disease, among others. CVDs are a leading cause of morbidity and mortality worldwide, affecting individuals of all ages and socioeconomic backgrounds.
Key Factors and Risk Factors:
Several factors contribute to the development of cardiovascular diseases. These include hypertension (high blood pressure), dyslipidemia (abnormal lipid levels), smoking, obesity, sedentary lifestyle, unhealthy diet, diabetes, and family history of CVDs. Age, gender, and genetic predisposition also play a role.
Impact and Consequences:
Cardiovascular diseases can have severe consequences on individuals and society as a whole. They often lead to serious complications such as heart attacks, strokes, heart failure, and premature death. Additionally, CVDs impose a substantial economic burden due to healthcare costs, lost productivity, and diminished quality of life for patients and their families.
Prevention and Management:
Prevention and management of cardiovascular diseases involve a comprehensive approach that addresses modifiable risk factors. Lifestyle modifications, including regular physical activity, a balanced diet, smoking cessation, and stress management, are crucial. Medications such as antihypertensives, lipid-lowering drugs, and anticoagulants may be prescribed to control risk factors and prevent complications. In some cases, surgical interventions such as angioplasty or bypass surgery may be necessary.
The latest findings from the China Cardiovascular Health and Disease Report 2021, released on June 23, 2022, shed light on the persistent prevalence and grave consequences of cardiovascular diseases (CVDs) in China. Despite advancements in healthcare, CVDs continue to maintain their position as the leading cause of morbidity and mortality in the country. The report revealed that in 2019, cardiovascular diseases were responsible for 46.74% of deaths in rural areas and 44.26% in urban areas, with a staggering 2 out of every 5 deaths attributed to CVDs.
At present, China has become one of the countries with the highest number of deaths from cardiovascular diseases in the world.
Magnitude of the Problem:
According to estimates provided by the report, the number of individuals affected by cardiovascular diseases in China is estimated to be a staggering 330 million. Among them, specific conditions such as stroke affect approximately 13 million individuals, coronary heart disease affects 11.39 million, heart failure affects 8.9 million, pulmonary heart disease affects 5 million, atrial fibrillation affects 4.87 million, rheumatic heart disease affects 2.5 million, congenital heart disease affects 2 million, lower limb arterial disease affects 45.3 million, and hypertension affects a staggering 245 million people.
These astonishing figures clearly demonstrate that the prevention and control of cardiovascular diseases in China remain in a critical state, with no apparent inflection point in sight. The burden imposed by CVDs on the healthcare system and society as a whole is immense, necessitating urgent and sustained efforts to combat this ongoing challenge.
The aforementioned report has identified five primary factors that can contribute to the development of cardiovascular diseases: a high-salt diet, smoking, consumption of spicy foods, frequent hotpot and barbecue meals, and a lack of physical activity, among others.
In the process of preventing cardiovascular diseases, it is crucial not only to improve our lifestyle habits but also to undergo regular physical examinations. These examinations serve as a vital means, especially in detecting risk indicators for cardiovascular diseases present in the blood. Such indicators can provide essential guidance for early prevention of cardiovascular diseases.
Lipid testing primarily involves quantitatively determining the lipid levels present in the blood. This test focuses on assessing the levels of total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in the serum.
The six key components of blood lipids that are measured during lipid testing include triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, apolipoprotein A, and apolipoprotein B.
Hzymes Biotech specializes in providing relevant raw materials and manufacturing services for biochemical testing reagent manufacturers in the field of cardiovascular disease diagnosis.
- Molecularly modified.
- esterases can be provided with different substrate selectivity to meet different customer needs.
- Provide technical solutions for high and low density reagents that can replace imported brands.
- Formulated high & low-density reagents are suitable for third-party quality control.
- Good compatibility with multi-manufacturer cholesterase.
- The specific vitality and thermal stability are comparable to imported brands.
High-density lipoprotein cholesterol (HDL-C) test kit (direct method)
- Core enzyme raw materials are completely self-produced.
- Clinical results can be compared with different brands of products, and the correlation is good.
- Strong anti-interference ability, good stability.
Low-density lipoprotein cholesterol (HDL-C) test kit(Direct Law)
- Core enzyme raw materials are completely self-produced.
- Compared with products from different brands, clinical results correlation is good
- Strong anti-interference ability
- Good stability.
In addition to the aforementioned indicators, it is necessary to also assess independent markers that can predict the risk of cardiovascular disease, such as homocysteine.
Homocysteine (Hcy) is a sulfur-containing amino acid present in the human body, which plays a vital role in the metabolism of methionine and cysteine. Many researchers consider elevated levels of homocysteine in the bloodstream as an autonomous risk factor for atherosclerosis. This condition can significantly increase the likelihood of stroke-related fatalities in approximately three-quarters of hypertensive patients.
The measurement of homocysteine has progressively become a mandatory diagnostic procedure during hospitalization in various medical facilities across China. Additionally, it is included as a routine component of physical examinations for individuals aged 40 and above. There are several factors contributing to the elevation of homocysteine levels in the body, including genetic defects, medical conditions, medication use, lifestyle choices, and other factors.
Hzymes Biotech offers essential raw materials for the Homocysteine Detection Reagent (Enzymatic Method) and provides original reagent manufacturing services.
Homocysteine Detection Reagent (Enzymatic Method)
- 1) Excellent performanceby Superior reagent formulation, formulated with lyophilized enzyme powder, comprehensive stability improvement.
- 2) Sealed and stored at 2-8 °C for more than 18 months, it can be stably stored in the machine for more than 35 days after opening.
- 3) The accuracy is high. R2 test results can reachmore than 0.99, compared with the of imported manufacturers.
We can customize the formula for you with different ratios, because we have mastered the core formula.
Cyst sulfate synthase (CBS), cyst sulfate lyase (CBL).
We can provide precise guidance on reagent dosage and minimize batch variations caused by the product form of the lyophilized enzyme powder, ensuring accurate quantification of the enzyme powder’s specific activity.
Our lyophilized enzyme powder offers excellent solubility and is resistant to thermal precipitation, thus significantly reducing the challenges associated with reagent development.
The high specific activity of our product, along with lower enzyme powder requirements and minimal interference, simplifies the reagent development process.
We can support customers in achieving self-production of the reagent by offering core enzyme raw materials and collaborative solutions for reagent formulation.
Our cystathionine synthase has the best half-life among similar products, and the reagents developed under the same system have better long-term stability. At the same time, our specific activity of the enzyme is the highest, which reduces the interference caused by the input of enzyme powder.
The half-life of our cystathionine lyase is the best among similar products, so the long-term stability of the reagents we developed under the same system is better.
When blood lipid risk factors progress to cardiovascular disease, damage to the myocardium and aorta becomes evident, particularly concerning myocardial damage.
Biochemical Myocardial Injury Detection
Biochemical myocardial injury detection involves various indicators, among which creatine kinase isoenzyme plays a vital role. Additionally, myoglobin and troponin serve as combined indices for chest pain detection, offering crucial insights for evaluating and diagnosing myocardial injury.
Significance of Creatine Kinase MB Isoenzyme (CK-MB)
Creatine kinase MB isoenzyme (CK-MB) is a hybrid dimer consisting of M and B subunits and stands out as the most specific enzyme in the myocardial enzyme profile. Its detection is instrumental in the early diagnosis of acute myocardial infarction (AMI) and is considered the “gold standard” for myocardial enzymatic diagnosis. The heightened activity of CK-MB in serum is widely recognized as a crucial indicator for diagnosing acute myocardial infarction and determining the presence or absence of myocardial necrosis.
CK-MB Detection Reagent Manufacturing Services by Hzymes Biotech
Hzymes Biotech offers original manufacturing services for CK-MB detection reagents (enzymatic), providing cutting-edge solutions in the field.
CK-MB detection reagent (enzymatic method)
- 1) Benchmark with first-class brands such as Desai and Beckman, and the accuracy of measurement is high;
- 2) Good stability of opening bottle, at least up to 30 days or so;
- 3) Clinical negative values are low.
Hzymes quality control in production is strictly in accordance with requirements of the industry regulations; Our process is stable, which can assure that the difference between batches is stable, and the results of different batches are qualified
At present, cardiovascular disease has become the first factor of death in China, and the demand for cardiovascular testing after chest pain diagnosis and blood lipid items during routine physical examination is growing. Hzymes biotech can provides a full set of testing raw materials and original reagent manufacturing services for in vitro diagnostic reagent manufacturers, and we are willing to work with industry colleagues to improve product quality, control production and manufacturing costs, and jointly cope with the impact of volume procurement. We look forward to contributing to the improvement of people health by provide more efficient and accurate detection reagents for hospitals and patients!